Namodenoson’s Favorable Safety Profile and Broad Patent Portfolio Positions it as a Promising Candidate in the Growing Obesity Treatment Market ...
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and ...
Can-Fite Biopharma Ltd (CANF) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting ...
Can-Fite BioPharma ( (CANF) ) just unveiled an update.
LAS VEGAS, NV / ACCESSWIRE / October 5, 2015 / What do Cemtrex, Inc. (CETX) and Can-Fite BioPharma Ltd. (CANF) have in common? They both made investors boatloads of money over the past month, with 100 ...
Hosted on MSN
Why Is Can-Fite BioPharma Stock (CANF) Up Today?
Can-Fite BioPharma (CANF) stock surged on Tuesday after the clinical-stage biopharmaceutical company provided an update on a patient treated with Namodenoson. Namodenoson is an investigational drug ...
The average one-year price target for Can-Fite BioPharma - Depositary Receipt (NYSEAM:CANF) has been revised to $3.46 / share. This is a decrease of 17.42% from the prior estimate of $4.19 dated ...
Nasdaq Analyst Research provides analyst research for ratings consensus and a summary of stock price targets. Analysts evaluate the stock’s expected performance in a given time period based on their ...
Can-Fite Biopharma Ltd. ADR Annual stock financials by MarketWatch. View the latest CANF financial statements, income statements and financial ratios.
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results